A Japanese medication used to treat new strains of this season's flu virus has demonstrated guarantee in being powerful against the coronavirus in clinical preliminaries, Japanese media gave an account of Wednesday.

Clinical experts in China said the antiviral medication favipiravir, created by an auxiliary of Fujifilm, has delivered empowering brings about clinical preliminaries in Wuhan and Shenzhen including 340 patients.

Contaminated patients who were given the medication in Wuhan and Shenzhen tried negative for the coronavirus following a middle of four days, contrasted and middle of 11 days for the individuals who were not treated with the medication.

Specialists additionally made the case that the lung condition in around 91 percent of the patients treated with favipiravir improved, contrasted with 62 percent of patients who didn't take the medication.

Specialists in Japan are purportedly utilizing a similar medication in clinical investigations on coronavirus patients with mellow to direct side effects.

Be that as it may, a Japanese wellbeing service source proposed the medication was not as compelling in individuals who experience progressively extreme manifestations, as indicated by The Guardian.

As of now, there is no treatment for the novel coronavirus that has contaminated more than 200,000 individuals worldwide and leftover 8,000 dead.

Specialists on Monday managed the primary shot in a preliminary for a potential immunization at the Kaiser Permanente Washington Health Research Institute in Seattle. The immunization was created by the National Institutes of Health (NIH) and its colleagues at Modern Inc., situated in Cambridge, Mass.

Yet, while the preliminary propelled for the current week, general wellbeing authorities have cautioned for quite a long time that an immunization won't be prepared for 12-year and a half in the best conditions.